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Estradiol reverses TGF-1–induced mesangial cell apoptosis by We have previously suggested that gender exerts a
a casein kinase 2-dependent mechanism. major impact on the rate of progression of chronic renal
Background. The slower rate of progression of chronic renal disease [1, 2]. To examine this hypothesis, we performeddisease in women than in men is explained in part by the ability
a meta-analysis examining the effect of gender on theof estradiol to reverse the stimulatory effect of transforming
rate of deterioration of renal function in non-diabeticgrowth factor-1 (TGF-1) on collagen IV synthesis at the level
of casein kinase 2 activation. Casein kinase 2 also phosphory- renal disease using 68 studies that contained a total of
lates and activates the pro-apoptotic protein, p53. We hypothe- 11,345 patients [3]. The results indicated that men with
sized that estradiol would reverse TGF-1–induced mesangial chronic renal failure show a more rapid decline in renalcell apoptosis by antagonizing the stimulatory effects of TGF-1
function with time than do women [3]. We then askedon casein kinase 2 activity, thereby preventing p53 activation.
whether sex-related differences in nephron supply con-Methods. The effects of TGF-1 on mesangial cell apoptosis,
p53 phosphorylation, Bax and Bcl-2 levels, caspase 9 activity, tribute to the increased susceptibility of males to progres-
and cleavage of PARP were examined. The abilities of estradiol sive renal injury, and found that genetically-determined
and a specific inhibitor of CK2 (5,6-dichloro-1--D-ribofurano-
differences in renal structure cannot explain this sexualsylbenzimidazole) (DRB) to modulate the effects of TGF-1
dimorphism [4]. On the other hand, sex hormones di-on these processes were also examined.
Results. TGF-1 (2 ng/mL), which up-regulates CK2 activ- rectly influence many of the processes implicated in renal
ity, induces apoptosis in murine mesangial cells together with disease progression, including mesangial cell matrix syn-
p53 serine389 phosphorylation, up-regulation of Bax, suppres- thesis and degradation, as well as the synthesis and re-
sion of Bcl-2, destabilization of mitochondrial permeability
lease of numerous cytokines and growth factors [1, 2].transition pores, stimulation of caspase 9 activity and activation
In animal models of renal disease, manipulation of theof PARP. TGF-1–induced p53 activation and all the interme-
diary steps leading to mesangial cell apoptosis were reversed hormonal milieu by gland ablation or by the administra-
by estradiol (109 mol/L) and by DRB, potent inhibitors of tion of exogenous sex hormones replicates the effects of
CK2 activity, but not by inhibitors of the p38 MAPK, ERK or gender on the course of chronic renal disease [1, 2].JNK signaling cascades. In contrast, TGF-1 failed to induce
These data suggest the impact of gender on renal diseaseapoptosis in p53 knockout mesangial cells.
progression may reflect direct receptor-mediated effectsConclusions. Our data suggest that CK2 mediates the stimu-
latory effects of TGF-1 on mesangial cell apoptosis via a of sex hormones [1, 2].
p53-dependent mechanism. The ability of estradiol to reverse Since transforming growth factor-1 (TGF-1) is the
TGF-1–induced apoptosis may contribute to the protective major mediator of the glomerulosclerosis that underlieseffects of female gender on the course of chronic renal disease.
progressive renal injury, we hypothesized that interac-
tions between estradiol and TGF-1 on collagen synthe-
sis may contribute to the protective effect of female gen-
der on the progression of renal disease. Our earlier studies
showed that physiologic concentrations of 17-estradiol
reversed the stimulatory effects of TGF-1 on type IV col-
Key words: gender and renal disease, transforming growth factor-,
lagen gene transcription and type IV collagen protein syn-apoptosis, progressive renal disease, chronic renal failure, type IV
collagen protein synthesis, sex hormones. thesis in a dose- and receptor-dependent manner [5, 6].
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important role in transducing signals between extracellu- nol, and analyzed by agarose gel electrophoresis followed
by staining with ethidium bromide to reveal the fragmen-lar growth factors and nuclear responses [7, 8]. The pre-
cise mechanisms whereby CK2 is regulated in vivo are tation pattern. Experimental reagents included TGF-1
2 ng/mL (R&D Systems, Minneapolis, MD, USA), es-unknown.
Our previous study showed that TGF-1 markedly tradiol 109 mol/L (Sigma Chemical Co., St. Louis, MO,
USA), 5,6-dichloro-1--D-ribofuranosylbenzimidazoleup-regulates CK2 activity in mesangial cells and that a
physiologic concentration of estradiol reverses the stimu- (DRB) 6 mol/L (Calbiochem, San Diego, CA, USA),
an inhibitor of casein kinase 2 activity [8], SB 203580 10latory effects of TGF-1 [9]. That study also demon-
strated that TGF-1 stimulates type IV collagen gene and 20 mol/L (Calbiochem), an inhibitor of the p38
mitogen-activated protein kinase cascade, curcumin 1transcription in murine mesangial cells by activating
CK2, which in turn interacts with the transcription fac- mol/L (Sigma), an inhibitor of both the extracellular
regulated kinase (ERK)/mitogen-activated protein ki-tors Egr-1 and Sp1 [9]. Estradiol antagonized the stimula-
tory effects of TGF-1 on CK2 which led to reversal of nase (MAPK) and the c-Jun N-terminal kinase (JNK)
cascades, PD 98059 50 mol/L (Calbiochem), a highlyTGF-1–stimulated type IV collagen gene transcription
and protein synthesis [9]. selective inhibitor of ERK/MAPK, and ICI 182780 106
mol/L (Tocris Cookson, St. Louis, MO, USA), a high-Apoptosis contributes to the development of glomeru-
losclerosis in chronic renal disease when deleted glomer- affinity estrogen receptor antagonist.
DNA fragmentation was confirmed utilizing the termi-ular cells are replaced by fibrosis [10–13]. Casein kinase 2
phosphorylates and activates the pro-apoptotic protein nal deoxynucleotidyl transferase (TdT)-mediated dUTP
nick end labeling (TUNEL) assay (ApoAlert DNA Frag-p53 [14–24]. We hypothesized that TGF-1 induces mes-
angial cell apoptosis by up-regulating casein kinase 2 mentation Assay Kit; Clontech Laboratories, Palo Alto,
CA, USA), by which fluorescein-dUTP incorporation atactivity, which in turn activates p53-dependent pro-apo-
ptotic pathways. We further hypothesized that estradiol the free ends of fragmented DNA can be visualized by
fluorescent microscopy [26]. Briefly, adherent cells wereantagonizes the TFG-1-induced apoptosis by reversing
TGF-1–stimulated CK2 activity. An anti-apoptotic ef- grown on coverslips and subjected to the experimental
conditions described. Cells were washed with PBS, fixedfect of estradiol in mesangial cells may contribute to
the observed protective effect of female gender on the with 4% formaldehyde/PBS for 30 minutes at 4C, per-
meabilized with 0.2% Triton X-100/PBS for 15 minutescourse of chronic renal disease.
at 4C, and incubated with a mixture of nucleotides and
TdT enzyme for 60 minutes at 37C in a dark, humidified
METHODS
chamber. The reaction was terminated with 2 standard
Mouse mesangial cells sodium citrate (SSC), the cells were washed with PBS, and
the coverslips were mounted on glass slides with Crystal/Glomeruli were isolated from male C57 B465 mice
(Jackson Laboratories, Bar Harbor, ME, USA). Mice were mount (Biomeda, Foster City, CA, USA). Fluorescent
nuclei were detected by visualization with a microscopeanesthetized and bilateral nephrectomies performed. After
mincing the cortical tissue, glomeruli were isolated by equipped with fluorescein filters (IX70; Olympus).
Phase-contrast microscopy was performed to confirmdifferential sieving and mesangial cells cultured by stan-
dard techniques [25]. For these experiments, cells were the presence of apoptosis. Cells were identified that satis-
fied the morphologic criteria for apoptosis including cellgrown in 2% fetal bovine serum (FBS) and used between
the third and tenth passages. Mesangial cells from p53 shrinkage, membrane blebbing and nuclear condensa-
tion. The percentage of apoptotic cells was determinedknockout mice were a gift from Dr. Stuart Shankland
(University of Washington, Seattle, WA, USA). after counting a total of 100 cells. Counts were repeated
three to five times per slide and the results averaged.
Apoptosis assays Experiments were repeated in triplicate. Results were
identical whether or not charcoal-stripped FBS was used,Internucleosomal DNA fragmentation was detected
by DNA laddering [26]. Briefly, nonadherent cells were and these data were combined.
pelleted, washed with phosphate-buffered saline (PBS),
Preparation of whole cell extractsand added to washed and scraped adherent cells. All
cells were pelleted, resuspended in 500 L of lysis buffer Mesangial cells were washed twice with PBS. The
washed cellular monolayer was incubated for 20 minutes[1% sodium dodecyl sulfate (SDS), 25 mmol/L ethylene-
diaminetetraacetic acid (EDTA), and 1 mg/mL protein- on a flat tray on a bed of crushed ice with 1 mL of lysis
buffer [50 mmol/L Tris-Cl, pH 8.0, 150 mmol/L NaCl,ase K, pH 8], and incubated overnight at 50C. Ribo-
nuclease A (10 mg/mL) was then added for an additional 0.02% sodium azide, 0.1% SDS, 100 g/mL phenylmeth-
ylsulfonyl fluoride (PMSF), 1 g/mL aprotinin, 1% Tri-two hour incubation at 37C. The chromosomal DNA was
extracted with phenol/chloroform, precipitated with etha- ton X-100, 0.5% sodium deoxycholate]. The resultant
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lysate was scraped into a chilled microcentrifuge tube, for differences in protein loading using -actin. Negative
controls using irrelevant antibodies and positive controlscentrifuged at 1200  g for 20 minutes, and the super-
natant stored at 70C. also were performed as indicated.
Caspase 9 activity assayWestern blotting
Western blotting was performed on total cellular pro- Caspase 9 activity was measured using a fluorescent
assay based on spectrophotometric detection of the chro-tein obtained from mesangial cells grown in phenol red-
free RPMI supplemented with 2% FBS. Protein content mophore p-nitroanilide (pNA) after cleavage from the
labeled substrate LEHD-pNA (Chemicon International,was measured in a 0.1 mL aliquot of the concentrated
media (BioRad Protein Assay; BioRad, Richmond, CA, Temecula, CA, USA). Briefly, apoptosis was induced by
exposure to TGF-1 in the presence or absence of the in-USA). To prepare the samples for SDS-polyacrylamide
gel electrophoresis (SDS-PAGE), 1 mL of 10% trichlo- dicated agents. Cells were suspended in 50 L of chilled
Cell Lysis Buffer (Chemicon), incubated on ice for 10roacetic acid was added to 4 mg protein of concentrated
media and the final volume brought to 2 mL with distilled minutes and then centrifuged at 10,000  g for one min-
ute. One hundred micrograms of supernatant protein werewater. The sample was vortexed and then centrifuged at
2000 rpm for 10 minutes. The pellet was dissolved in 1 mL diluted to 50 L and incubated with 5 L of 4 mmol/L
LEHD-pNA substrate and 50 L Reaction Buffer (Chem-of loading buffer (2% SDS, 10% glycerol, 50 mmol/L
Tris, 3% bromophenol blue, 2% -mercaptoethanol, pH icon) containing 10 mmol/L dithiothreitol (DTT) for two
hours at 37C. Spectrophotometric readings were obtained7.6), boiled for five minutes, and then immediately placed
on ice. Twenty-five, 50, 75 or 100 g of sample were at 405 nmol/L. Background readings from cell lysates
and buffers were subtracted from sample readings.loaded for electrophoretic separation of proteins. SDS-
PAGE was performed by standard techniques and pro-
Mitochondrial transition pore permeabilityteins transferred to a polyvinylidene difluoride micropo-
rous membrane. Apoptosis was induced by exposure to TGF-1 in the
Western blotting of mesangial cell nuclear extracts was presence and absence of the indicated agents. An un-
performed using rabbit anti-human phospho-p53 (ser392 ; treated negative control and a positive control were also
Oncogene, Boston, MA, USA), mouse monoclonal anti- assayed. Cells were rinsed with serum-free media. Re-
human p53 (Oncogene), mouse monoclonal anti-human agent was prepared by adding 1 L MitoSensor (Clon-
Bcl-2 (Santa Cruz BioTechnology, Santa Cruz, CA, USA), tech) to 1 mL incubation buffer (5 g/mL, final concen-
rabbit polyclonal anti-human Bax (Santa Cruz), rabbit tration) and vortexed. Cells were covered with 1 mL of
anti-human cytochrome C (Santa Cruz), and goat poly- diluted reagent in six-well plates and incubated at 37C
clonal anti-human poly (ADP-ribose) polymerase (PARP; in a 5% CO2 incubator for 15 to 20 minutes. Cells were
Santa Cruz). rinsed with incubation buffer and examined under a mi-
After blotting, the membrane was immediately placed croscope using a band-pass filter to detect fluorescein and
into blocking buffer [2% bovine serum albumin (BSA) rhodamine. The assay uses a cationic dye that fluoresces
in wash buffer consisting of 10 mmol/L Tris, 100 mmol/L differently in apoptotic and nonapoptotic cells. In healthy
NaCl, 0.1% Tween 20] on a shaking apparatus for 30 cells, the dye is taken up in the mitochondria, where it
minutes at 37C. The membrane was next washed for 30 forms aggregates that exhibit intense red fluorescence
minutes with agitation and then placed in 5% non-fat when visualized via fluorescence microscopy. However,
milk in wash buffer containing the appropriate secondary in apoptotic cells exhibiting altered mitochondrial mem-
antibody conjugated to horseradish peroxidase (Sigma). brane potentials, the dye is unable to aggregate in the
The antibody conjugate was allowed to incubate for 30 mitochondria. As a result, the dye remains in monomeric
minutes at 37C with agitation. After washing, the mem- form in the cytoplasm, where it fluoresces green.
brane was treated with Enhanced Chemiluminescence
StatisticsReagent (Amersham Life Science, Arlington Heights,
IL, USA) according to the manufacturer’s instructions. For each individual data point, the mean of at least
Kodak X-OMAT 4R film (Eastman Kodak, Rochester, five experiments was calculated. The data are means 
NY, USA) was exposed to the blot for 10 minutes. Bands SEM. Differences among groups were tested by analysis
were quantitated by laser densitometry. Membranes of variance with Scheffe’s correction. P  0.05 was con-
were then washed and reprobed with monoclonal anti- sidered a significant difference.
body directed against -actin (Sigma).
The amount of protein loaded into each lane was con-
RESULTSfirmed to be within the linear range of detection by West-
Transforming growth factor-1 2 ng/mL at 24 hoursern blotting in our system. All Western blotting data are
expressed as a percent of control values after correcting induced apoptosis in cultured wild-type murine mesan-
Negulescu et al: Gender and renoprotection in CRF1992
mediated mechanism (Fig. 3). PD 98059 50 mol/L, a
selective inhibitor of ERK/MAPK, failed to reverse
TGF-1–induced apoptosis at 24 hours (Fig. 3).
Transforming growth factor-1 2 ng/mL at 24 hours
destabilized mitochondrial transition pores as indicated
by a cytoplasmic staining pattern in the MitoSensor assay
(Fig. 4). A mitochondrial staining pattern was restored
by estradiol 109 mol/L and by DRB 6 mol/L, but not
by SB 203580 10 or 20 mol/L, or curcumin 1 mol/L
at 24 hours.
TGF-1 2 ng/mL had no effect on p53 protein levels at
24 hours (101 2; PNS; Fig. 5A). Neither a physiologic
concentration of estradiol 109 mol/L, DRB 6 mol/L, SB
203580 10 or 20 mol/L, or curcumin 1 mol/L, alone
(96  2, 102  1, 102  3, 103  3, respectively) or in
combination with TGF-1 (96 7, 94 2, 101 1, 100
10, respectively) had any effect on p53 protein levels at
24 hours.
Twenty-four hours of TGF-1 2 ng/mL increased Ser389
phospho-p53 levels (195  11, expressed as a percent of
values obtain in control, untreated mesangial cells grown
in serum-free, phenol red-free RPMI; P 0.001; (Fig. 5B).
TGF-1–induced phosphorylation of Ser389 p53 was re-
versed by estradiol 109 mol/L (106  5, P  0.001 vs.
TGF-1 alone) and by DRB 6 mol/L (103  4, P 
0.001 vs. TGF-1 alone), but not by SB 203580 10 or
20 mol/L (178  21, P  NS vs. TGF-1 alone), or by
curcumin 1mol/L (164 17, PNS vs. TGF-1 alone)
at 24 hours. Estradiol 109 mol/L, DRB 6 mol/L, SB
203580 10 or 20 mol/L, or curcumin 1 mol/L alone
Fig. 1. At 24 hours, transforming growth factor-1 (TGF-1; 2 ng/mL) had no effect on p53 phosphorylation at 24 hours.induces apoptosis in murine mesangial cells as assessed by DNA lad-
At 24 hours, TGF-1 2 ng/mL reduced Bcl-2 levels indering. TGF-1–induced mesangial cell apoptosis is reversed by estra-
diol 109 mol/L and by DRB 6 mol/L, but not by SB 203580 10 or 20 cultured murine mesangial cells (35  6, expressed as a
mol/L, or curcumin 1 mol/L. (B ) TGF-1 2 ng/mL fails to induce percent of values obtained in control, untreated mesan-apoptosis in p53 knockout mesangial cells at 24 hours. Abbreviations
gial cells grown in serum-free, phenol red-free RPMI,are: E, estradiol; DRB, 5,6-dichloro-1--D-ribofuranosylbenzimidazole;
SB, SB 203580; Cur, curcumin. P  0.001; Fig. 5C). TGF-1–induced suppression of
Bcl-2 levels was reversed by estradiol 109 mol/L (103 
2, P  0.001 vs. TGF-1 alone) and by DRB 6 mol/L
(103  3, P  0.001 vs. TGF-1 alone), but not by SBgial cells as assessed by DNA laddering (Fig. 1A). This
203580 10 or 20 mol/L (31  10, P  NS vs. TGF-1TGF-1–induced apoptosis was reversed by a physio-
alone), or by curcumin 1 mol/L (31  8, P  NS vs.logic concentration of estradiol 109 mol/L and by DRB
TGF-1 alone) at 24 hours. Estradiol 109 mol/L, DRB,6 mol/L, an inhibitor of CK2 activity at 24 hours. SB
SB 203580 10 or 20 mol/L, or curcumin 1 mol/L, alone203580 10 or 20 mol/L, an inhibitor of the p38 MAPK
had no effect on Bcl-2 levels (101  1, 105  6, 100  1,cascade, and curcumin 1mol/L, an inhibitor of the ERK
101  1, respectively) at 24 hours.and JNK pathways, had no effect on TGF-1–induced
Transforming growth factor-1 2 ng/mL increased Baxapoptosis at 24 hours. In contrast, 24 hours of TGF-1
levels (164 12, expressed as a percent of values obtained2 ng/mL failed to induce apoptosis in mesangial cells
in control, untreated mesangial cells grown in serum-free,from p53 knockout mice (Fig. 1B). The results of DNA
phenol red-free RPMI, P  0.01) at 24 hours (Fig. 5D).laddering experiments were confirmed with the TUNEL
TGF-1–induced up-regulation of Bax was reversed byassay (Fig. 2) and phase-contrast microscopy (Fig. 3).
estradiol 109 mol/L (94  10, P  0.02 vs. TGF-1In additional studies utilizing both the TUNEL assay
alone) and by DRB 6 mol/L (101  9, P  0.05 vs.and phase contrast microscopy, ICI 182780, a high-affin-
TGF-1 alone), but not by SB 203580 10 or 20 mol/Lity estrogen receptor antagonist (106 mol/L), reversed
(173  18, P  NS vs. TGF-1 alone) or curcumin 1the protective effects of estradiol (109 mol/L) on TGF-1–
induced apoptosis at 24 hours, suggesting a receptor- mol/L (168  13, P  NS vs. TGF-1 alone) at 24
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Fig. 2. At 24 hours TGF-1 2 ng/mL induces apoptosis in murine mesangial cells as assessed by the TUNEL assay. The TGF-1–induced mesangial
cell apoptosis is reversed by estradiol 109 mol/L and DRB 6 mol/L, but not by SB 203580 10 or 20 mol/L, or curcumin 1 mol/L. Abbreviations
are in the legend to Figure 1.
Fig. 3. Transforming growth factor-1 2 ng/mL
induces apoptosis in murine mesangial cells
as assessed by phase-contrast microscopy at
24 hours. Data are expressed as percent apo-
ptotic cells. TGF-1–induced apoptosis is re-
versed by DRB 6 mol/L and by estradiol
109 mol/L, but not by PD 98059 50 mol/L,
curcumin 1 mol/L, or SB 203580 10 or 20
mol/L. ICI 182780 106 mol/L, a high affin-
ity estrogen receptor antagonist, reversed the
protective effect of estradiol 109 mol/L on
TGF-1–induced apoptosis. Abbreviations are:
E, estradiol; I, ICI 182780; PD, PD 98059;
Cur, curcumin; SB, SB 203580, and DRB, 5,
6-dichloro-1--D-ribofuranosylbenzimidazole.
hours. Estradiol 109 mol/L, DRB 6 mol/L, SB 203580 cumin 1 mol/L. Estradiol 109mol/L, DRB 6 mol/L,
10 or 20 mol/L or curcumin 1 mol/L alone had no SB 203580 10 or 20 mol/L, or curcumin 1 mol/L alone
effect on Bax levels at 24 hours (98  9, 96  6, 108  had no effect on PARP at 24 hours.
4, 102  4, respectively).
Transforming growth factor-1 2 ng/mL stimulated
DISCUSSIONcaspase 9 activity compared to control cells grown in
While TGF-1 promotes apoptosis in most cell typesserum-free, phenol red-free RPMI at 24 hours (437  9
[27–42], it protects other cells from apoptosis-inducingvs. 4  2 optical density units  103, P  0.001; Fig. 6A).
agents [43–47] and is without effect in yet other cellAt 24 hours TGF-1-stimulated caspase activity was
types [42]. The mechanism whereby TGF-1 promotesreversed by estradiol 109 mol/L (9  4, P  0.001 vs.
apoptosis is also cell type-specific. Both p53-dependentTGF-1 alone) and by DRB 6 mol/L (5  3, P  0.001
[33, 38, 42] and p53-independent mechanisms have beenvs. TGF-1 alone), but not by SB 203580 10 or 20mol/L
identified [32, 38, 40]. Generation of reactive oxygen(396  3, P  NS vs. TGF-1 alone) or by curcumin
metabolites [35, 48, 49] and inhibition of pRb expression1 mol/L (363 5, PNS vs. TGF-1 alone). Estradiol
[30] have been implicated in the induction of apoptosis109 mol/L, DRB 6 mol/L, SB 203580 or curcumin
by TGF-1. TGF-1 has been shown to modulate the1 mol/L alone had no effect on caspase 9 activity (10 
expression or activity of various components of the apo-2, 16  19, 19  10, 10  5, respectively).
ptotic pathway [27–41, 46–49]. In a cell type-specific man-Transforming growth factor-1 2 ng/mL at 24 hours
ner, TGF-1 reduces Bcl-2 and Bcl-xl levels, increasesinduced cleavage of the 112 kD protein PARP into
Bax and Bik levels, increases the expression and/or ac-its 85 kD activated form (Fig. 6B). Activation of PARP
tivity of p53, reduces the expression or increases thewas reversed by estradiol 109 mol/L and by DRB 6
mol/L, but not by SB 203580 10 or 20 mol/L, or cur- phosphorylation of retinoblastoma protein, destabilizes
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Fig. 4. TGF-1 2 ng/mL destabilizes mitochondrial transition pores as indicated by a cytoplasmic staining pattern in the Mito Sensor assay at
24 hours (second panel). A mitochondrial staining pattern is restored by estradiol 109 mol/L (third panel) and by DRB 6 mol/L (last panel),
but not by SB 203580 10 or 20 mol/L or curcumin 1 mol/L (not shown).
mitochondrial membrane permeability transition pores to mic activation of the ERK pathway and suppression of
the JNK pathway [58, 59, 64]. In contrast, ER promotesrelease cytochrome C into the cytoplasm, activates Apaf-1/
caspase apoptosome complexes, increases the expression apoptotic activity via either activation of the JNK path-
way, which in turn phosphorylates and inactivates Bcl-2and/or up-regulates the activity of caspases 3, 8 and 9,
and reduces c-myc levels [27–41, 44, 46–49]. and Bcl-xl (MCF-7 cells) [59], or alternatively via Fas/Fas
ligand interactions and activation of caspace 3 (neuronalWhile estradiol protects most cell types from apopto-
sis-inducing agents [39, 50–61], estradiol induces apopto- cells) [64]. In substantia nigral neurons, which exclusively
express ER, estrogen protects against apoptosis-pro-sis in other cells and is without effect in yet other cell
types [42, 62–65]. The mechanism whereby estradiol in- moting agents by inhibiting activator protein-1 (AP-1)–
dependent transcription independent of estrogen re-hibits apoptosis is also cell type-specific. Estradiol modu-
lates the expression or activity of various components sponse element-dependent transcription [60].
p53 has been identified as an important mediator ofof the apoptotic pathway [39, 50, 55–58, 61–64]. ERK
activation and suppression of the c-Jun N-terminal ki- apoptosis [42]. The DNA binding activity of p53 has been
localized to its carboxyterminal region [23]. Adjacent tonase or p38 cascades have been implicated in the anti-
apoptotic effects of estradiol [50, 59]. In a cell type- this domain is a conserved serine (ser392 in humans, ser389
in rats and mice) that is a substrate for phosphorylationspecific manner, estradiol alters the expression of various
members of the Bcl-2 family (increased Bcl-2 and Bcl-xl by CK2 and PKC. Phosphorylation of p53 by CK2 in-vitro
activates the function of p53 [14, 15, 17, 18, 20–24, 68,levels, reduced Bak and Bax levels) [39, 42, 50–59, 61–64].
In this context, the Bcl-2 gene contains two non-consen- 69]. However, there is controversy surrounding the in
vivo consequences of ser392 phosphorylation [17]. Phos-sus estrogen response elements downstream from its pro-
moter [53, 65]. Estradiol also suppresses the activity of phorylation of ser392 or substitution of a glutamic or aspar-
tic acid residue to simulate phosphorylation enhancescaspase 3 and 9, increases levels of phosphorylated reti-
noblastoma protein, increases Nip-2 levels, and increases tetramerization of p53 and activates its DNA binding
and transcriptional activity [14, 15, 17, 18, 20–24, 68, 69].the expression of c-myc in various cell types [42, 51, 54,
57, 66]. Of particular interest, activation of p53 by phosphoryla-
tion of ser389 by CK2 mediates tumor necrosis factor-	We have shown that mesangial cells express both the
	 and  isotypes of the estrogen receptor [67]. Several (TNF-	)–induced apoptosis [22]. In contrast, substitu-
tion of ser389 with a neutral amino acid results in theinvestigators have suggested that the 	 isotype (ER	)
mediates estradiol’s anti-apoptotic actions via non-geno- loss of transrepressional activity, loss of the ability to
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Fig. 5. (A) Neither TGF-1 2 ng/mL, estradiol 109 mol/L, DRB 6 mol/L, SB 203580 10 or 20 mol/L, or curcumin 1 mol/L, alone or in com-
bination alter p53 levels at 24 hours. (B) TGF-1 2 ng/mL induces phosphorylation of p53 at ser389. TGF-1–induced phosphorylation of p53 is
reversed by estradiol 109 mol/L and by DRB 6 mol/L, but not by SB 203580 10 or 20 mol/L or curcumin 6 mol/L at 24 hours. (C ) TGF-1
2 ng/mL suppresses Bcl-2 levels in murine mesangial cells at 24 hours. The effects of TGF-1 are reversed by estradiol 109 mol/L and by DRB
6 mol/L, but not by SB 203580 10 or 20 mol/L, or curcumin 1 mol/L at 24 hours. (D) TGF-1 2 ng/mL increases Bax levels in murine mesangial
cells. The effects of TGF-1 are reversed by estradiol 109 mol/L and by DRB 6 mol/L, but not by SB 203580 10 or 20 mol/L or curcumin
1 mol/L at 24 hours. Abbreviations are: T, transforming growth factor-1; E, estradiol; D, 5,6-dichloro-1--D-ribofuranosylbenzimidazole; S, SB
203580; C, curcumin.
suppress cellular proliferation and loss of transforming membrane glomerulonephritis, apoptosis is associated
with resolution of glomerular proliferation and progres-capability [15, 19–21].
A major pathway that transduces apoptosis is medi- sion to glomerular sclerosis [11]. The number of apopto-
tic glomerular cells increase in parallel with the develop-ated by destabilization of mitochondrial permeability
transition pores, resulting in the release of cytochrome ment of progressive glomerular sclerosis in the remnant
kidney model [10, 11, 13]. In biopsy specimens fromC into the cytosol where it forms a ternary complex
with Apaf-1 and procaspase 9 [27, 41]. Bcl-2 antagonizes patients with IgA nephropathy and systemic lupus ery-
thematosus, the number of apoptotic glomerular cellsapoptosis by stabilizing mitochondrial permeability tran-
sition pores, thus blocking the release of cytochrome C, correlate with the glomerulosclerosis index and loss of
renal function [11]. Similarly, apoptosis plays an impor-and by binding to and inactivating Apaf-1 [27, 41]. In
contrast, Bax promotes apoptosis by destabilizing mito- tant role in the development of renal tubular atrophy and
progressive loss of interstitial tissue in an experimentalchondrial permeability transition pores [70].
Although apoptosis serves a beneficial function in pro- model of ureteral obstruction [12].
We have previously shown that TGF-1 stimulatesmoting the resolution of glomerular hypercellularity dur-
ing the repair process of anti-Thy 1.1 glomerulonephritis, collagen IV gene transcription and protein synthesis in
murine mesangial cells by up-regulating CK2 activity andapoptosis promotes the replacement of glomerular cells
with extracellular matrix in the later stages of glomerular subsequent interactions with the transcription factors
Egr-1 and Sp1 [9]. Non-phosphorylated Egr-1 binds toinjury [13]. In experimental anti-glomerular basement
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phosphorylation of p53 at ser389. Ser389 is a specific sub-
strate for CK2 and protein kinase C, but not for other
serine/threonine kinases. Antibody directed against ser-
ine392 of human p53 also recognizes serine389 of mouse p53,
but does not recognize phosphorylation of other serine
residues in p53 [17]. Thus, the antibody we utilized to as-
sess phosphorylation of p53 specifically measured phos-
phorylation of the serine residue that is a substrate for
CK2 (ser389) and which stimulates the pro-apoptotic ac-
tivity of p53. Moreover, TGF-1–induced p53 phosphor-
ylation was reversed by a specific inhibitor of CK2 and by
estradiol, which is also a potent inhibitor of CK2 activity.
Our data indicate that TGF-1–induced apoptosis is
mediated via a p53-dependent mechanism, since TGF-1
failed to induce apoptosis in p53 knockout mesangial
cells. However, at higher concentrations of TGF-1, Pa-
tel et al found that TGF-1 induces apoptosis in mesan-
gial cells via both p53-dependent and p53-independent
mechanisms that involve nitric oxide generation [38].
Transforming growth factor-1–induced apoptosis
was demonstrated by DNA laddering and confirmed by
TUNEL assay and phase-contrast microscopy. Phosphor-
ylation of p53 by TGF-1 led to destabilization of mi-
tochondrial transition pores, up-regulation of Bax, sup-
pression of Bcl-2, stimulation of caspase 9 activity, and
cleavage of PARP. A physiologic concentration of estra-
diol or a specific CK2 inhibitor reversed the TGF-1–
induced phosphorylation of p53 and protected mesangial
Fig. 6. (A) TGF-1 2 ng/mL up-regulates caspase 9 activity in murine
cells from TGF-1–induced apoptosis. Blockade of CK2mesangial cells at 24 hours. The effects of TGF-1 are reversed by
estradiol 109 mol/L and by DRB 6 mol/L, but not by SB 203580 10 and prevention of apoptosis by estradiol or DRB was
or 20 mol/L, or curcumin 1 mol/L. (B ) TGF-1 2 ng/mL causes associated with stabilization of mitochondrial transition
PARP 112 kD to be cleaved into its 85 kD active form. The effect of
pores, normalization of Bax and Bcl-2 levels, and reversalTGF-1 is reversed by estradiol 109 mol/L and by DRB 6 mol/L,
but not by SB 203580 10 or 20 mol/L, or curcumin 1 mol/L at 24 of caspase 9 activation and PARP cleavage.
hours. Abbreviations are: T or TGF, transforming growth factor-1; E, Although p38 and JNK have been identified as media-
estradiol; D or DRB, 5,6-dichloro-1--D-ribofuranosylbenzimidazole;
tors of TGF-1–induced apoptosis in various cell typesS or SB, SB 203580; C or Cur, curcumin.
[46], these pathways play no role in murine mesangial cells.
In addition to inhibiting p38 MAPK, Laping and Olson
reported that SB 203580 also inhibits TGF- type I re-
and sequesters Sp1, which reduces the amount of free ceptor kinase activity with an IC50 value of 16 mol/L
Sp1 available to bind to DNA and transactivate gene (abstract; J Am Soc Nephrol 10:575A, 1999). In light of
transcription, whereas phosphorylated Egr-1 is unable to this observation, it is unclear why SB 203580 fails to re-
bind Sp1. TGF-1 activates CK2 and increases CK 2-medi- verse the ability of TGF-1 to induce cellular apoptosis in
ated phosphorylation of Egr-1. Phosphorylation of Egr-1 murine mesangial cells (this study), up-regulate 	-smooth
leads to decreased Egr-1/Sp1 complex formation, in- muscle actin in human lung fibroblasts [71], or up-regulate
creased unbound Sp1, increased binding of mesangial SMAD 7 mRNA in rat kidney fibroblasts [72].
cell nuclear extracts to a Sp1 consensus binding sequence Our demonstration that TGF-1 destabilizes mito-
in the type IV collagen promoter, and increased type IV chondrial permeability transition pores suggests that the
collagen gene transcription and protein synthesis [9]. mitochondrial pathway is involved in the induction of
Physiologic concentrations of estradiol reversed TGF-1– mesangial cell apoptosis by TGF-1. Of interest, physio-
stimulated CK2 activity and all these subsequent events logic concentrations of estradiol also reverse TGF-1–
[9]. These data suggest that CK2 may be a general media- induced apoptosis in rat hepatocytes [39]. The induction
tor of TGF-1 actions that integrates TGF-1and estra- of apoptosis by TGF-1 in these cells and its reversal
diol signaling. by estradiol are associated with alterations in cytosolic
Our current study demonstrates that TGF-1 induces cytochrome C, also suggesting an involvement of the
mitochondrial pathway.apoptosis in murine mesangial cells in association with
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